Substance / Medication

Susoctocog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Successful hemodialysis initiation in acquired hemophilia a managed with susoctocog alfa and emicizumab.
Kihara Ayano, Tamaki Masanori, Sumitani Ryohei et al. · CEN Case Rep · 2025
PMID: 41436689Case ReportFull text (PMC)
Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection.
Fernández-Oliveira Carla, Rotea-Salvo Sandra, Fernández-Docampo Marta et al. · Eur J Hosp Pharm · 2023
PMID: 34011555Case ReportFull text (PMC)
Successful perioperative prophylaxis with susoctocog alfa in a patient with acquired haemophilia A: A case study.
Buczma Anna, Baran Beata, Korwin Magdalena et al. · Haemophilia · 2022
PMID: 34878208Case Report
Susoctocog Alfa: A Review in Acquired Haemophilia A.
Burness Celeste B, Scott Lesley J · Drugs · 2016
PMID: 27098420Review
Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A.
Heeg Justus, Dobbelstein Christiane, Iorio Alfonso et al. · J Thromb Haemost · 2025
PMID: 40812597Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Susoctocog alfa (substance)
SNOMED CT
725746009
UMLS CUI
C3859426

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.